Glaxo Group Limited, UK has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Glaxo Group Limited, UK, on behalf of the promoter group of GlaxoSmithKline Pharmaceuticals, has filed a regulatory disclosure confirming compliance with SEBI's takeover regulations for the financial year ended March 31, 2025. The promoter group — comprising Glaxo Group Limited, GlaxoSmithKline Pte Ltd, Burroughs Wellcome International Limited, and ESKAYLAB LIMITED — has declared that no encumbrance was created on shares held in the company during the financial year. The filing further confirms that as of March 31, 2025, there are no shares of the company that are encumbered or pledged by the promoters.
This is a routine annual compliance filing that confirms the promoter group's shares in GSK Pharma are completely unencumbered and free of any pledges. It is a neutral, positive governance signal showing the promoter group has not used its stake as collateral, which can be reassuring for retail investors concerned about promoter-level risk.